Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02675946
Title	CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Recruitment	Unknown status
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Curegenix Inc.
Indications	pancreatic adenocarcinoma Advanced Solid Tumor colorectal adenocarcinoma hepatocellular carcinoma bile duct carcinoma gastric adenocarcinoma esophageal carcinoma
Therapies	CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib
Age Groups:	adult \| senior
Covered Countries	USA